TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06202469

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement 1
Description: Creatine monohydrate (5 g/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement 2
Description: Creatine monohydrate (5 g/day) plus ubiquinol (200 mg/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (inulin)
Study: NCT05235165

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of tissue and blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of tissue and blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05768425

Intervention type: DIAGNOSTIC_TEST
Intervention: Motor examination
Description: Unified Parkinsons Rating Scale (UPDRS)

Intervention type: DIAGNOSTIC_TEST
Intervention: Motor examination
Description: Unified Parkinsons Rating Scale (UPDRS)
Study: NCT05872295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IKS014
Description: IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IKS014
Description: IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IKS014
Description: IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IKS014
Description: IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IKS014
Description: IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IKS014
Description: IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent.
Study: NCT05019755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A002(IN-115314) capsule
Description: Oral Administration of IN-A002(IN-115314), single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A002(IN-115314) capsule
Description: Oral Administration of IN-A002(IN-115314), single dose
Study: NCT05507060

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibrating MESH nebulizer (Aerogen Ultra)
Description: Medication will be applied with Vibrating MESH nebulizer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jet nebulizers (Philips Respironics)
Description: Medication will be applied with Jet nebulizers
Study: NCT06256029

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recruitment maneuver
Description: The recruitment maneuver will be performed by increasing the current peak pressure (Ppeak) by 5 cm H2O, changing the inspiratory/expiratory ratio from 1:2 to 1:1, with PEEP values of 5 and 7 cm H2O. The respiratory rate during the recruitment maneuver will be 10 breaths per minute, and the recruitment maneuver will last 30 seconds (5 breaths). The recruitment maneuver will be performed 3 times: the first time immediately after the formation of the pneumoperitoneum and the positioning of the patient in the reverse Trendelenburg position with a PEEP of 5 cm H2O, the second time with a PEEP of 7 cm H2O, during the duration of the operation. The third recruitment maneuver will be performed with a PEEP of 7 cm H2O at the end of the operative procedure, and immediately before the patient wakes up. After each increase, PEEP will be maintained at higher pressure values with a peak value of 7 cm H2O.
Study: NCT05424887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK3280
Description: Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
Study: NCT06518369

Intervention type: OTHER
Intervention: Prehabilitation
Description: Prehabilitation program for 4-6 weeks before surgery will include:~* Review of the frailty risk analysis calculator score obtained in the frailty study (#2212-74)~* Review of lab results including complete blood count, creatinine, albumin, and prealbumin~* Review of chronic conditions.~* An office visit or telehealth visit to review instructions on instructions on nutrition, exercise, smoking cessation, and optimization of chronic disease.~* Drinking surgery immunonutrition drinks twice daily for 5 days before surgery.~* Educational information and video instruction~* Weekly phone calls to motivate, ensure adherence, and assess progress.~* Measurements of hand grip strength and body weight
Study: NCT04997616

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Happy Lane Hemp Extract/CBD soft gels (25 mg/capsule)
Description: Half of the study participants (5 women and 5 men) will be taking one gel capsule per day (25 mg/day dose), while the other half (5 women and 5 men) will be taking 2 gel capsules per day (50 mg/day dose). Study participants will be taking gel capsules for 10 consecutive days. At the end of this 10-day regimen, study participant will return to the TRI where blood specimen (up to 15 mL) will be collected within 2 to 6 hours after the last dose. Major plant cannabinoids and cannabinoid metabolites in each blood specimen will be determined using liquid chromatography-mass spectrometry.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Happy Lane Hemp Extract/CBD soft gels (25 mg/capsule)
Description: Half of the study participants (5 women and 5 men) will be taking one gel capsule per day (25 mg/day dose), while the other half (5 women and 5 men) will be taking 2 gel capsules per day (50 mg/day dose). Study participants will be taking gel capsules for 10 consecutive days. At the end of this 10-day regimen, study participant will return to the TRI where blood specimen (up to 15 mL) will be collected within 2 to 6 hours after the last dose. Major plant cannabinoids and cannabinoid metabolites in each blood specimen will be determined using liquid chromatography-mass spectrometry.
Study: NCT05405374

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OSTEOAMP
Description: OSTEOAMP SELECT Fibers (derived from human bone allograft) rehydrated with bone marrow aspirate (BMA) and combined with local autogenous graft for use in lumbar interbody fusion of the lumbar spine.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infuse
Description: The Infuse Bone Graft/Medtronic Interbody Fusion Device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2, known as dibotermin alfa) placed on an absorbable collagen sponge (ACS). rhBMP-2 is the active agent in the Infuse Bone Graft component. The ACS is a soft, white, pliable, absorbent implantable matrix for rhBMP-2.
Study: NCT05402813

Intervention type: OTHER
Intervention: Pure Tone Audiometry Assessment
Description: Collection of Pure Tone Audiometry data performed in routine practice during study period

Intervention type: OTHER
Intervention: Pure Tone Audiometry Assessment
Description: Collection of Pure Tone Audiometry data performed in routine practice during study period

Intervention type: OTHER
Intervention: Pure Tone Audiometry Assessment
Description: Collection of Pure Tone Audiometry data performed in routine practice during study period

Intervention type: OTHER
Intervention: Quality of Life Questionnaires
Description: Collection of Quality of Life questionnaire's answers during study period

Intervention type: OTHER
Intervention: Quality of Life Questionnaires
Description: Collection of Quality of Life questionnaire's answers during study period

Intervention type: OTHER
Intervention: Quality of Life Questionnaires
Description: Collection of Quality of Life questionnaire's answers during study period
Study: NCT05872724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy + Adjuvant chemotherapy and Zimberelimab
Description: * Radiation therapy:~  1. Irradiation mode and dose: 6MV-X-ray (6Megavoltage-X-ray), IMRT or RapidArc-IMRT were used for external radiotherapy. External radiotherapy dose: PTV (Planning Target Volume) 45-50Gy/25 times.~* Chemotherapy:~  1. Concurrent chemotherapy: Cisplatin monotherapy: DDP 75 mg/m2 for 3 days, q3w. Carboplatin or nedaplatin may be used in patients that cannot tolerate cisplatin.~ 2. Adjuvant chemotherapy: After the concurrent chemoradiotherapy, 4 cycles of consolidation chemotherapy plus immunotherapy are recommended for patients with high risk or MRDc0 (+). Recommended chemotherapy regimen: liposome paclitaxel 135mg/m2 d1 +DDP 25 mg/m2 D1-3, Q21.~* Zimberelimab injection:~  240 mg, IV, q3w. Start the drug one day before the start of postoperative radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (small pelvic) + Zimberelimab
Description: Radiation therapy:~1. Target volume of radiotherapy for small pelvis: CTVp includes tumor bed area, paracentral area and part of vagina; CTVn includes bilateral internal iliac, external iliac and obturator lymphatic drainage areas. Upper boundary to sacroiliac joint level, lower boundary to 2cm below vaginal stump.~Chemotherapy:~Concurrent chemotherapy: Cisplatin monotherapy: DDP 75 mg/m2 for 3 days, q3w. Carboplatin or nedaplatin may be used in patients that cannot tolerate cisplatin.~Adjuvant chemotherapy: After the concurrent chemoradiotherapy, 4 cycles of adjuvant immunotherapy are recommended for patients in good general condition (ECOG: 0-1) with medium risk and MRDc0 (-).~Zimberelimab injection: 240 mg, IV, q3w. Start the drug one day before the start of posterior radiotherapy.
Study: NCT05948592

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TP-102
Description: Patients randomised to TP-102 will receive 1 (one) mL of IP solution, applied topically per cm3 of target ulcer. The titre of each bacteriophage in TP-102 is 1x109 PFU/mL (\>1x108 PFU/mL and \<1x1010 PFU/mL). All patients randomised to TP-102 will receive the same concentration per mL. TP-102 will be applied to the target ulcer using a syringe without a needle. The volume of TP-102 to be administered will be determined from the wound volume assessment at the previous visit through an automated wound measurement system (Silhouette), except on the first day of treatment where the amount applied will be determined based on the wound volume determined at that time using the automated wound measurement system (Silhouette).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomised to placebo, the volume calculated to be administered will be determined from the wound volume assessment at the previous visit through an automated wound measurement system (Silhouette), except on the first day of treatment where the amount applied will be determined based on the wound volume determined at that time using the automated wound measurement system (Silhouette).
Study: NCT04650113

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MTA material
Description: Partial pulpotomy is a procedure in which the inflamed tissue beneath an exposure is removed to a depth of 1 to 3 mm or deeper to reach healthy pulp tissue.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: MTA material
Description: Partial pulpotomy is a procedure in which the inflamed tissue beneath an exposure is removed to a depth of 1 to 3 mm or deeper to reach healthy pulp tissue.
Study: NCT05748119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEB-1170
Description: Depending on the dosage, either 20 mg, 40 mg capsules, or a combination of both
Study: NCT05235165

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracoscopy
Description: Undergo video-assisted thoracoscopic surgery or VATS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracotomy
Description: Undergo open thoracic surgery
Study: NCT06163287

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement
Description: Dietary supplement containing molecular hydrogen
Study: NCT05748119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEB-1170
Description: Depending on the dosage, either 20 mg, 40 mg capsules, or a combination of both

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEB-1170
Description: Depending on the dosage, either 20 mg, 40 mg capsules, or a combination of both

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEB-1170
Description: Depending on the dosage, either 20 mg, 40 mg capsules, or a combination of both
Study: NCT05685433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eCoin Tibial Nerve Stimulation
Description: Subcutaneous stimulation of the tibial nerve using the eCoin device.
Study: NCT05748119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEB-1170
Description: Depending on the dosage, either 20 mg, 40 mg capsules, or a combination of both

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEB-1170
Description: Depending on the dosage, either 20 mg, 40 mg capsules, or a combination of both

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEB-1170
Description: Depending on the dosage, either 20 mg, 40 mg capsules, or a combination of both

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEB-1170
Description: Depending on the dosage, either 20 mg, 40 mg capsules, or a combination of both

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEB-1170
Description: Depending on the dosage, either 20 mg, 40 mg capsules, or a combination of both

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MEB-1170
Description: Depending on the dosage, either 20 mg, 40 mg capsules, or a combination of both

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEB-1170
Description: Depending on the dosage, either 20 mg, 40 mg capsules, or a combination of both

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEB-1170
Description: Depending on the dosage, either 20 mg, 40 mg capsules, or a combination of both

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEB-1170
Description: Depending on the dosage, either 20 mg, 40 mg capsules, or a combination of both

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEB-1170
Description: Depending on the dosage, either 20 mg, 40 mg capsules, or a combination of both

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEB-1170
Description: Depending on the dosage, either 20 mg, 40 mg capsules, or a combination of both

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEB-1170
Description: Depending on the dosage, either 20 mg, 40 mg capsules, or a combination of both
Study: NCT06163287

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert substance
Study: NCT06581575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCXH-105
Description: IM injection
Study: NCT05748119

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent number and size of capsules containing placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent number and size of capsules containing placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent number and size of capsules containing placebo
Study: NCT06545565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium acetate group will receive sodium acetate in the neonatal PN.
Description: This group will receive sterile sodium acetate daily in the neonatal PN for the duration the patient will receive parenteral nutrition, a maximum of 28 days of life.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium chloride group will receive sodium chloride in the neonatal PN.
Description: This group will receive sterile sodium chloride daily in the neonatal PN for the duration the patient will receive parenteral nutrition, a maximum of 28 days of life.
Study: NCT05748119

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent number and size of capsules containing placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent number and size of capsules containing placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent number and size of capsules containing placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent number and size of capsules containing placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent number and size of capsules containing placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent number and size of capsules containing placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent number and size of capsules containing placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent number and size of capsules containing placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent number and size of capsules containing placebo
Study: NCT06581575

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix
Description: IM injection
Study: NCT06206850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Oral Osimertinib 80 mg once daily (QD) for the duration of 9 weeks (3 cycles).
Study: NCT06116708

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kalogon AF Prototype Smart Cushion
Description: The Kalogon cushion is a dynamic smart cushion that utilizes a combination of foam and 5 adjustable air cells to intelligently redistribute weight and increase comfort for users. The air cells are used to modulate interface pressures and adjust where support or pressure reductions are provided based on input from the controller's pressure sensing system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Seat Cushion from Air Force
Description: This is the standard seat cushion that was provided by the United States Air Force to use for this study. It is a high-density, molded polyurethane foam.
Study: NCT06516315

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative ultrasound examination.
Description: Preoperative ultrasound examination performed the day before or the day of surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peroperatoire angiography procedure and QFR analysis
Description: Intraoperative angiography will be performed immediately prior to revascularization. Quantitative analysis of angiography images will be performed post-procedure using Medis QFR®2.2 software.
Study: NCT04676334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib will be administered daily.
Study: NCT06169384

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic adenoidectomy
Description: Subjects will be randomly assigned into two groups (30 patient each group): Group A will undergo endoscopic partial adenoidectomy using the 70◦ rigid endoscope trans-orally and shaver (microdebrider) ,by removing the upper (choanal) part only with leaving the lower part of the adenoid .(2) Group B will undergo total adenoidectomy ,by removing all the adenoid lymphoid tissue .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic adenoidectomy
Description: Subjects will be randomly assigned into two groups (30 patient each group): Group A will undergo endoscopic partial adenoidectomy using the 70◦ rigid endoscope trans-orally and shaver (microdebrider) ,by removing the upper (choanal) part only with leaving the lower part of the adenoid .(2) Group B will undergo total adenoidectomy ,by removing all the adenoid lymphoid tissue .
Study: NCT04174846

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ready-to-use therapeutic food (RUTF)
Description: SAM children will receive approximately 190 kcal/kg/day of standard RUTF

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-to-use-supplementary food (RUSF)
Description: SAM children will receive approximately 190 kcal/kg/day of Acha Mum (AM-RUSF)
Study: NCT06006741

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MM-specific universal CAR T cells
Description: Infusion of MM-specific universal CAR T cells
Study: NCT05424887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK3280
Description: Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK3280
Description: Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
Study: NCT06271122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Voluntary activation assessed by magnetic stimulation
Description: Visits V1 (Day 1) and V2 (Day 28) are identical. The dominant leg will be tested, the patient positioned on the ergometer and EMG electrodes placed on the quadriceps.~The familiarization for femoral magnetic stimulation (FMS) will begin, the stimulation site identified and the supramaximality verified.~After a warm up, the subject will perform 3 maximal voluntary isometric contractions (MVIC; 5s, rest = 30s), 3 MVIC reaching maximal force as quickly as possible, and 4 MVIC during which magnetic stimulation (intensity = 100%) will be applied during the contraction and 2 seconds after the contraction ends.~For transcranial magnetic stimulation, the stimulation area and intensity will be determined. After that, the patient will perform 3 CMIV at 100%, 75%, 50% and 35% of CMIV. During each contraction, magnetic stimulation will be delivered during the force plateau.
Study: NCT06032468

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARC Intellicare
Description: wearable devices to guide rehabilitation exercise
Study: NCT05424887

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
Study: NCT06032468

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation sheets
Description: rehabilitation exercise sheets to guide rehabilitation exercise
Study: NCT04996017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg in 20 ML Injection
Description: Atezolizumab will be supplied as sterile liquid in 20-mL glass vials. The vial is designed to deliver 20 mL (1200 mg) of atezolizumab solution but may contain more than the stated volume to enable delivery of the entire 20 mL volume. For information on the formulation and handling of atezolizumab, refer to the Atezolizumab Investigator's Brochure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as sterile liquid in 20ml vials. the vial is designed